Evaluation of nanobody-based biologics targeting purinergic checkpoints in tumor models
AAV vectors
P2X7
anti-tumor immune responses
nanobody
nanobody-based biologics
purinergic signaling
tumor microenvironment (TME)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
05
08
2022
accepted:
03
10
2022
entrez:
7
11
2022
pubmed:
8
11
2022
medline:
9
11
2022
Statut:
epublish
Résumé
Adenosine triphosphate (ATP) represents a danger signal that accumulates in injured tissues, in inflammatory sites, and in the tumor microenvironment. ATP promotes tumor growth but also anti-tumor immune responses notably
Identifiants
pubmed: 36341324
doi: 10.3389/fimmu.2022.1012534
pmc: PMC9626963
doi:
Substances chimiques
Adenosine Triphosphate
8L70Q75FXE
Adenosine
K72T3FS567
Oxaliplatin
04ZR38536J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1012534Informations de copyright
Copyright © 2022 Demeules, Scarpitta, Hardet, Gondé, Abad, Blandin, Menzel, Duan, Rissiek, Magnus, Mann, Koch-Nolte and Adriouch.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. FK-N is a co-inventor on a patent application on P2X7-specific nanobodies. FK-N, SM, YD, BR, and TM are co-inventors on a patent application on CD73-specific nanobodies.
Références
Sci Transl Med. 2016 Nov 23;8(366):366ra162
pubmed: 27881823
Front Oncol. 2020 Sep 11;10:1699
pubmed: 33042812
Front Pharmacol. 2018 Feb 01;9:39
pubmed: 29449813
Front Immunol. 2018 Jul 09;9:1580
pubmed: 30038627
Nat Commun. 2017 Sep 21;8(1):647
pubmed: 28935898
Nature. 2001 Dec 20-27;414(6866):916-20
pubmed: 11780065
J Immunol. 2007 Jul 1;179(1):186-94
pubmed: 17579037
Pharmacol Rev. 2014 Jul;66(3):638-75
pubmed: 24928329
Oncogene. 2019 May;38(19):3636-3650
pubmed: 30655604
EMBO J. 2021 Jul 1;40(13):e108130
pubmed: 34121201
Curr Opin Pharmacol. 2020 Aug;53:98-100
pubmed: 32861959
PLoS One. 2014 Sep 16;9(9):e107224
pubmed: 25226385
Theranostics. 2020 Aug 29;10(24):10849-10860
pubmed: 33042257
FASEB J. 2007 Nov;21(13):3490-8
pubmed: 17575259
Trends Cell Biol. 2018 May;28(5):392-404
pubmed: 29439897
Nat Commun. 2016 May 10;7:11523
pubmed: 27161080
Cancer Res. 2015 Feb 15;75(4):635-44
pubmed: 25542861
Biochem Pharmacol. 2018 May;151:234-244
pubmed: 29288626
PLoS One. 2012;7(7):e41269
pubmed: 22848454
J Immunol. 2009 Mar 1;182(5):2898-908
pubmed: 19234185
J Exp Med. 2010 Nov 22;207(12):2561-8
pubmed: 20975043
J Virol. 2015 Aug;89(16):8334-45
pubmed: 26041300
Mol Biol Cell. 2005 Jul;16(7):3260-72
pubmed: 15901833
Br J Pharmacol. 2006 Jan;147 Suppl 1:S172-81
pubmed: 16402102
Trends Immunol. 2012 May;33(5):231-7
pubmed: 22487321
Sci Immunol. 2018 Dec 14;3(30):
pubmed: 30552101
Purinergic Signal. 2009 Jun;5(2):139-49
pubmed: 19255877
Immunol Lett. 2019 Jan;205:16-24
pubmed: 30439478
J Autoimmun. 2010 Mar;34(2):145-54
pubmed: 19796917
Front Chem. 2018 Jun 28;6:248
pubmed: 30003075
Nat Med. 2009 Oct;15(10):1170-8
pubmed: 19767732
Eur J Haematol. 2014 Aug;93(2):172-4
pubmed: 24766221
Blood. 1997 Aug 15;90(4):1600-10
pubmed: 9269779
Front Immunol. 2018 Jan 23;8:1989
pubmed: 29410663
Immunol Lett. 2006 Jan 15;102(1):98-105
pubmed: 16207496
Methods Mol Biol. 2022;2510:99-127
pubmed: 35776322
Cancer Discov. 2019 Dec;9(12):1754-1773
pubmed: 31699796
Front Immunol. 2017 Nov 14;8:1526
pubmed: 29184552
Cell Rep. 2019 May 21;27(8):2411-2425.e9
pubmed: 31116985
Curr Opin Pharmacol. 2020 Aug;53:126-133
pubmed: 33002857
Cancer Res. 2015 Mar 1;75(5):835-45
pubmed: 25564520
J Clin Invest. 2020 Mar 2;130(3):1185-1198
pubmed: 31770109
Immunity. 2003 Oct;19(4):571-82
pubmed: 14563321
Cancer Immunol Res. 2020 Mar;8(3):356-367
pubmed: 31992567
Curr Med Chem. 2017;24(21):2261-2275
pubmed: 28266268
Front Immunol. 2015 May 19;6:204
pubmed: 26042119
Cancer Discov. 2020 Jan;10(1):40-53
pubmed: 31732494
Nat Rev Cancer. 2018 Oct;18(10):601-618
pubmed: 30006588
FASEB J. 2010 Sep;24(9):3393-404
pubmed: 20453110
Immunity. 2017 Jul 18;47(1):15-31
pubmed: 28723547
Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7
pubmed: 16916931
Biomed J. 2019 Jun;42(3):141-154
pubmed: 31466708
Curr Opin Pharmacol. 2019 Aug;47:59-64
pubmed: 30921559
Cancer Discov. 2020 Jan;10(1):16-19
pubmed: 31919119
Front Pharmacol. 2020 Jun 04;11:793
pubmed: 32581786
Front Mol Neurosci. 2018 Jul 31;11:265
pubmed: 30108481
Nat Med. 2014 Mar;20(3):296-300
pubmed: 24509526
Curr Opin Pharmacol. 2019 Aug;47:110-118
pubmed: 30986625
Nat Biotechnol. 1997 Jul;15(7):637-40
pubmed: 9219265
Blood. 1998 Aug 1;92(3):946-51
pubmed: 9680363
Cells. 2021 Jan 19;10(1):
pubmed: 33477845
Immunol Rev. 2017 Mar;276(1):121-144
pubmed: 28258700